Oxytocin
Hormonal and Signaling
ABOUT
Oxytocin is a peptide hormone and prescription medicine. The current U.S. product label describes specific obstetric uses under clinical supervision; it is not a general-purpose wellness, social, or performance product.
EVIDENCE OVERVIEW
Supported by controlled human trials
WHAT THIS MEANS
Established. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
Oxytocin is a nine-amino-acid posterior-pituitary hormone acting at the oxytocin receptor, a G-protein-coupled receptor on uterine myometrium and mammary myoepithelial cells. It produces rhythmic uterine contraction and milk ejection. The social and behavioural effects it is popularly associated with are a separate, far less established literature from its approved obstetric use.
PHARMACOKINETICS
Plasma half-life is short, in the range of a few minutes, which is why the approved use is a controlled intravenous infusion titrated to uterine response rather than a fixed dose. It is destroyed in the gastrointestinal tract, so oral administration is not effective.
REVIEW
PUBLISHED PAIR RECORDS
No published, curated interaction record is available for this compound in the current library.
HUMAN EVIDENCE
FDA-approved by intravenous infusion for the initiation or improvement of uterine contractions where this is medically indicated, and for control of postpartum bleeding. Its use in labour is long established and closely monitored. Intranasal oxytocin for social, autism or bonding indications is not approved and the trial literature there is inconsistent - that is a different route, dose and evidence base from the approved product.
REPORTED EFFECTS
The label carries a boxed warning that oxytocin is not indicated for elective induction of labour. Serious labelled risks include uterine hypertonicity, spasm, tetanic contraction and uterine rupture, fetal bradycardia and arrhythmias, and - because oxytocin has intrinsic antidiuretic effect - severe water intoxication with convulsions and coma when given with excessive fluid volume. Anaphylaxis and postpartum haemorrhage are also listed.
RESEARCH LIMITATIONS
This evidence and labelling apply to licensed medical products and specified obstetric contexts. They do not establish safety or benefit for non-prescription preparations, non-obstetric uses, or self-directed administration. Peppy does not provide dosing guidance.
CURATED SOURCES · 1
Explore library